![]() Introduced in 2001, the CMS NTAP program was created by Congress to support timely access to innovative therapies used to treat Medicare beneficiaries in the hospital inpatient setting. hospitals and further supports making Andexxa the standard of care for patients who experience major, life-threatening bleeds." "We believe the proposed extension will help broaden patient access to Andexxa in U.S. "CMS' recommendation to extend NTAP designation aligns with our ongoing efforts and broader mission to expand access to Andexxa, the first and only FDA-approved reversal agent for the Factor Xa inhibitors rivaroxaban or apixaban," said Sheldon Koenig, Portola's chief commercial officer. Finalization of the proposed continuation of NTAP status for Andexxa would go into effect on October 1, 2020. Public comments on the proposal will be accepted through July 10, 2020, and CMS is expected to release the final rule on or around September 1, 2020. ![]() The proposed rule concerning the Hospital Inpatient Prospective Payment System and CMS Fiscal Year 2021 was released on Monday, ( ), and will be published in the Federal Register on May 29, 2020. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® through federal fiscal year 2021, for eligible Medicare beneficiaries treated in the inpatient hospital setting. Andexxa, first approved for use in the United States in May 2018, received its NTAP designation effective October 1, 2018. ![]() SOUTH SAN FRANCISCO, Calif., /PRNewswire/ - Portola Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |